Bluejay Diagnostics has developed the Symphony platform, a near-patient biomarker detection system designed to enhance healthcare outcomes by providing rapid and quantitative clinical chemistry results essential for triage and acute care. Symphony integrates traditional enzyme-linked immunosorbent assay (ELISA) methodology with modern advancements in nanotechnology and microfluidics. This innovative design allows for fast, simple, and highly sensitive biomarker detection, requiring only a few drops of blood to yield results in approximately 20 minutes. The system's single-use cartridges contain all necessary reagents and facilitate whole blood processing, which streamlines the testing process and reduces the need for specialized training or expensive laboratory infrastructure.

The Symphony platform operates on a 'sample-to-result' format, where the specimen is placed directly into the cartridge, which is then inserted into the analyzer for testing without further technician intervention. This design not only simplifies the testing process but also makes it accessible to healthcare facilities that may not have the resources for more complex diagnostic systems. The Symphony platform's compact and cost-effective nature allows for simultaneous testing of multiple samples or biomarkers, making it a valuable tool for improving patient testing in time-sensitive and critical situations.

United States

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient product for triage and monitoring of disease progression. 

Bluejay Diagnostics

Company Details